CAPREOMYCIN

US Previously Marketed

First approved in 1971

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050095s062lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/20154709

Capreomycin is an antibiotic, which is used in combination other antituberculosis drugs fro the treatment of pulmonary infections caused by capreomycin-susceptible strains of M. tuberculosis when the primary agents (isoniazid, rifampin, ethambutol, aminosalicylic acid, and streptomycin) have been ineffective or cannot be used because of toxicity or the presence of resistant tubercle bacilli. Little is known about capreomycin's exact mechanism of action, but it is thought to inhibit protein synthesis by binding to the 70S ribosomal unit. Capreomycin also binds to components in the bacterial cell which result in the production of abnormal proteins.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
70S ribosome 16 Target ID: CHEMBL2363965 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20154709	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pulmonary infections 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050095s062lbl.pdf	Curative		Approved 8429	CAPASTAT SULFATE Approved Use Capastat Sulfate, which is to be used concomitantly with other appropriate antituberculosis agents, is indicated in pulmonary infections caused by capreomycin-susceptible strains of M. tuberculosis when the primary agents (isoniazid, rifampin, ethambutol, aminosalicylic acid, and streptomycin) have been ineffective or cannot be used because of toxicity or the presence of resistant tubercle bacilli. Susceptibility studies should be performed to determine the presence of a capreomycin-susceptible strain of M. tuberculosis. Launch Date 1971

PubMed

Title	Date	PubMed
Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis.	1998 May	9593173
Capreomycin in the treatment of atypical mycobacterial disease in HIV-positive patients.	2002 Jul	12172753
Capreomycin is active against non-replicating M. tuberculosis.	2005 Apr 1	15804353
Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis.	2005 Aug	16048924
Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2'-O-methylations in 16S and 23S rRNAs.	2006 Jul 21	16857584
Capreomycin--a polypeptide antitubercular antibiotic with unusual binding properties toward copper(II).	2012 Jan	22112847

Patents

Sample Use Guides

In Vivo Use Guide

Intravenously: Capastat Sulfate (Capreomycin for Injection) should be diluted in 100 mL of 0.9% Sodium Chloride Injection and administered over 60 minutes. Intramuscularly — Reconstituted Capastat Sulfate should be given by deep intramuscular injection into a large muscle mass, since superficial injection may be associated with increased pain and the development of sterile abscesses. For administration of a 1-g dose, the entire contents of the vial should be given. For doses lower than 1 g, the following dilution table may be used.

Route of Administration: Other

In Vitro Use Guide

Unknown

Substance Class	Mixture Created by `admin` on `Fri Dec 15 15:41:08 GMT 2023` Edited by `admin` on `Fri Dec 15 15:41:08 GMT 2023`
Record UNII	232HYX66HC
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CAPREOMYCIN

Official Name

English

CAPREOMYCIN [HSDB]

Common Name

English

CAPREOMICIN

Common Name

English

Capreomycin [WHO-DD]

Common Name

English

CAPREOMYCIN [MI]

Common Name

English

CAPOSTATIN

Common Name

English

capreomycin [INN]

Common Name

English

CAPASTAT

Brand Name

English

CAPREOMYCIN [VANDF]

Common Name

English

CAPROMYCIN

Common Name

English

Classification Tree Code System Code

WHO-VATC

QJ04AB30